Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm
Source: Streetwise Reports 09/26/2018
This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia.
RepliCel Life Sciences Inc. (
Once the deal closes, the two companies can begin efforts to commercialize RepliCel’s products in Greater China, which encompasses mainland China, Hong Kong, Macau and Taiwan.
“We are very excited about what we have put in place,” RepliCel president and CEO R. Lee Buckler said in a news release. “Upon the closing of the investment, shareholders should expect to see RepliCel’s programs and activity gain significant momentum over the coming months with a particular focus on bringing its medical device to market.”
The investment consists of YOFOTO purchasing CA$5.09 million worth of RepliCel common shares at CA$0.09 apiece and a 20% warrant exercisable at CA$0.95 per share for two years. YOFOTO also will make milestone and sales royalty payments and will finance, over the next five years, certain RepliCel programs and construction of a cell processing facility in Greater China.
Those programs include further development and commercialization in the East Asian region of RepliCel’s tendon regeneration cell therapy (RCT-01), its skin rejuvenation cell therapy (RCS-01) and its injection technology for dermal applications (RCI-02). (RCI-2 as a hair restoration treatment is excluded.) Once the transaction closes, RepliCel will provide an update with details of the path forward.
Read what other experts are saying about:
- RepliCel Life Sciences Inc.
Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: RepliCel Life Sciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of RepliCell Life Sciences, a company mentioned in this article.
( Companies Mentioned:
)
Read Next
